Addressing Patent Enablement Issues Post Amgen

Time: 12:00 - 1:00 p.m. ET
Location: Online

The session will review the recent Amgen Supreme Court Decision, which found that Amgen's patent covering its cholesterol lowering drug Repatha invalid for lack of enablement. The claims of the patent are broadly directed to an antibody that binds certain epitopes on the PCSK9 enzyme. The session will involve analyzing the Supreme Court's rationale for lack of enablement, and explore its impact on patenting strategies for life science discoveries more generally.

Webinars are complimentary for AUTM Members, but you must Register and check out of your cart to receive login details. Not a member yet? Join Today!